Bausch + Lomb's Saunders doesn't expect more big deals in the near term

Aug 2 (Reuters) - Eye care firm Bausch + Lomb does not expect to do another big deal for around a year after it completes its $1.75 billion deal for dry eye drug Xiidra, recently rehired chief executive Brent Saunders said on Wednesday.